Portal de Periódicos da CAPES

Optical imaging spectroscopy for rapid, primary screening of SARS-CoV-2: a proof of concept

2022; Nature Portfolio; Volume: 12; Issue: 1 Linguagem: Inglês

10.1038/s41598-022-06393-3

2045-2322

Emilio Gómez-González, Alejandro Barriga‐Rivera, Beatriz Fernández‐Muñoz, Jose Manuel Navas-Garcia, Isabel Fernández-Lizaranzu, Francisco Javier Munoz-Gonzalez, Rubén Parrilla Giráldez, Desirée Requena-Lancharro, Pedro Gil-Gamboa, Cristina Rosell‐Valle, Carmen Gómez-González, María José Mayorga-Buiza, María Martín-López, Olga Muñoz, Juan Carlos Gómez Martı́n, María Isabel López, Jesus Aceituno-Castro, Manuel A. Perales‐Esteve, Antonio Puppo-Moreno, Francisco Garcı́a-Cózar, Lucia Olvera-Collantes, Raquel Gómez‐Díaz, Silvia de los Santos-Trigo, Monserrat Huguet-Carrasco, Manuel Rey, Emília Gómez, Rosario Sánchez‐Pernaute, Javier Padillo-Ruíz, Javier Márquez-Rivas,

Biosensors and Analytical Detection

Abstract Effective testing is essential to control the coronavirus disease 2019 (COVID-19) transmission. Here we report a-proof-of-concept study on hyperspectral image analysis in the visible and near-infrared range for primary screening at the point-of-care of SARS-CoV-2. We apply spectral feature descriptors, partial least square-discriminant analysis, and artificial intelligence to extract information from optical diffuse reflectance measurements from 5 µL fluid samples at pixel, droplet, and patient levels. We discern preparations of engineered lentiviral particles pseudotyped with the spike protein of the SARS-CoV-2 from those with the G protein of the vesicular stomatitis virus in saline solution and artificial saliva. We report a quantitative analysis of 72 samples of nasopharyngeal exudate in a range of SARS-CoV-2 viral loads, and a descriptive study of another 32 fresh human saliva samples. Sensitivity for classification of exudates was 100% with peak specificity of 87.5% for discernment from PCR-negative but symptomatic cases. Proposed technology is reagent-free, fast, and scalable, and could substantially reduce the number of molecular tests currently required for COVID-19 mass screening strategies even in resource-limited settings.